U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07036029) titled 'NAL ER IPF Respiratory Function and Safety Study' on May 29.
Brief Summary: The primary purpose of this study is to assess the safety and tolerability of escalating doses of NAL ER and to evaluate its effect on respiratory function in participants with IPF.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Idiopathic Pulmonary Fibrosis
Intervention:
DRUG: NAL ER
Oral tablets
DRUG: Placebo
Oral tablets
Recruitment Status: RECRUITING
Sponsor: Trevi Therapeutics
Disclaimer: Curated by HT Syndication....